12 / 18
PFS by prior endocrine therapy status
Probability of PFS (%)
26
22 20
16
12 10 8 6 4 2 0
18
14
24
0
20
40
60
80
100
Time (months)
Probability of PFS (%)
26
18 16 14 12 10 8 6 4 2 0
20 22 24
0
20
40
60
80
100
Time (months)
First line*
Second line + early relapsers
‡
PFS
(investigator
assessment)
Ribociclib +
fulvestrant
n=236
Placebo +
fulvestrant
n=109
Events, n (%)
131 (55.5)
84 (77.1)
Median PFS,
months
14.6
9.1
Hazard ratio
(95% CI)
0.565 (0.428–0.744)
PFS (investigator
assessment)
Ribociclib +
fulvestrant
n=238
Placebo +
fulvestrant
n=129
Events, n (%)
76 (31.9)
66 (51.2)
Median PFS,
months
NR
18.3
Hazard ratio
(95% CI)
0.577 (0.415–0.802)
No. at risk
Ribociclib + fulvestrant
Placebo + fulvestrant
238
129
205
109
189
99
180
91
173
88
166
85
159
78
149
75
141
68
97
40
49
18
31
10
7
4
0
0
No. at risk
Ribociclib + fulvestrant
Placebo + fulvestrant
236
109
188
83
167
67
159
63
143
54
132
47
117
36
104
29
91
25
55
12
28
8
20
4
5
0
0
0
*Treatment naive for ABC;
‡
Received up to 1 line of prior endocrine therapy for ABC.